07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Moving on

It is not often that the evolution of a biotech company follows the script, but Movetis N.V. (Euronext: MOVE) has done just that. Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago,...
07:00 , Aug 9, 2010 |  BioCentury  |  Finance

Moving On

It is not often that the evolution of a biotech company follows the script, but Movetis N.V. (Euronext: MOVE) has done just that. Since being spun out from Johnson & Johnson (NYSE:JNJ) three-plus years ago,...
02:01 , Jan 9, 2007 |  BC Extra  |  Financial News

Movetis raises EUR 49 million

Movetis (Vosselaar, Belgium), a gastrointestinal specialty pharma spinout from Johnson & Johnson (JNJ), raised EUR 49 million ($64.7 million) in a series A round led by Sofinnova Partners and Life Science Partners. Other investors include...
08:00 , Jan 8, 2007 |  BioCentury  |  Finance

Ebb & Flow

Cowen was no slouch on the biotech financing front in 2006, underwriting at least $2 billion of the sector's IPOs, follow-ons and private placements/registered directs. Now, the firm hopes to add another leg to its...
08:00 , Jan 8, 2007 |  BioCentury  |  Strategy

Making GI moves

A new spinout from Johnson & Johnson , gastrointestinal specialty pharma company Movetis N.V. , was expected to announce on Monday this week that it raised E49 million ($64.7 million) in a series A round...